• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.

    4/24/25 5:10:03 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care
    Get the next $EPRX alert in real time by email
    6-K 1 f6k_042425.htm FORM 6-K
     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 6-K

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of April 2025

    Commission File Number: 001-41923

    EUPRAXIA PHARMACEUTICALS INC.
    (Exact name of Registrant as specified in its charter)

    N/A
    (Translation of Registrant’s name)

    201-2067 Cadboro Bay Road
    Victoria, British Columbia, Canada V8R 5G4
    Telephone: (250) 590-3968 

    (Address and telephone number of registrant’s principal executive office)

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
    Form 20-F [   ]      Form 40-F [ X ]

     

     


    DOCUMENTS INCLUDED AS PART OF THIS REPORT

    Exhibit  
      
    99.1 Press Release dated April 24, 2025


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      EUPRAXIA PHARMACEUTICALS INC.
       
      
    Date: April 24, 2025 By: /s/ Alex Rothwell                     
      Name: Alex Rothwell
      Title: Chief Financial Officer
      
    Get the next $EPRX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EPRX

    DatePrice TargetRatingAnalyst
    7/24/2025$11.00Overweight
    Cantor Fitzgerald
    6/26/2025$12.00Buy
    H.C. Wainwright
    6/16/2025Speculative Buy
    Canaccord Genuity
    2/21/2025$12.00Buy
    Craig Hallum
    11/14/2024$9.00Buy
    Rodman & Renshaw
    More analyst ratings

    $EPRX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Eupraxia Pharmaceuticals Inc.

    SCHEDULE 13G/A - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Subject)

    11/14/25 4:37:06 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    SEC Form SCHEDULE 13G filed by Eupraxia Pharmaceuticals Inc.

    SCHEDULE 13G - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Subject)

    11/14/25 9:10:51 AM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    SEC Form 6-K filed by Eupraxia Pharmaceuticals Inc.

    6-K - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Filer)

    11/13/25 5:00:06 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    $EPRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI

    The 52-week symptom data reported for Cohort 6 patients is consistent with the long-term durability data previously reported from Cohort 5; Cohorts 5 & 6 are the only groups to reach 52 weeks thus far.In Cohort 6, a durable clinical symptom response was observed 52 weeks after a single administration of EP-104GI.All 3 patients in Cohort 6 maintained a clinical benefit and 2 out of 3 patients remain in clinical remission 52 weeks after treatment of EoE with EP-104GI.In combination with patients from Cohort 5, at 52 weeks, 4 out of 6 patients remain in clinical remission.At week 36, 67% of all patients in the trial that were measured at 36 weeks, were in clinical remission (Cohorts 5-7, n=9).O

    11/13/25 5:00:00 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results

    Durable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-104GI Enrollment continues in Phase 2b portion of the RESOLVE Trial, with topline data expected by Q3 2026 Completed $80.5 million public offering supported by leading life science investors Cash runway to fund pipeline development and operations into the first half of 2028 VICTORIA, British Columbia, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize local, controlled drug delivery for diseases with significant unmet ne

    11/4/25 4:39:26 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs

    Clinical data was reported for the first time in patients receiving an 8 mg dose per injection (Cohort 9 of the dose escalation portion of RESOLVE), the highest dose planned in this trial. Patients in Cohort 9 experienced the largest improvements in tissue health outcomes and eosinophil reduction observed to date.RESOLVE Safety Committee and members of the Eupraxia Clinical Advisory Board endorsed using the 8 mg dose per injection as the second dose for the ongoing Phase 2b portion of the RESOLVE study.Eupraxia intends to expand the EP-104GI development program, including increasing the number of patients in the Phase 2b portion of RESOLVE from 60 to at least 120 patients.Eupraxia intends t

    9/29/25 5:00:00 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    $EPRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Eupraxia Pharmaceuticals with a new price target

    Cantor Fitzgerald initiated coverage of Eupraxia Pharmaceuticals with a rating of Overweight and set a new price target of $11.00

    7/24/25 7:27:25 AM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    H.C. Wainwright initiated coverage on Eupraxia Pharmaceuticals with a new price target

    H.C. Wainwright initiated coverage of Eupraxia Pharmaceuticals with a rating of Buy and set a new price target of $12.00

    6/26/25 8:10:08 AM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    Canaccord Genuity initiated coverage on Eupraxia Pharmaceuticals

    Canaccord Genuity initiated coverage of Eupraxia Pharmaceuticals with a rating of Speculative Buy

    6/16/25 11:20:22 AM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    $EPRX
    Financials

    Live finance-specific insights

    View All

    Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

    Announced first patient dosed in the Phase 2b placebo-controlled portion of the EP-104GI RESOLVE trial with topline data expected in H2 2026Announced positive data from Phase 1b/2a RESOLVE supporting the potential of EP-104GI to improve the standard of care for patients with Eosinophilic Esophagitis ("EoE")Additional data from cohorts 5–8 from Phase 1b/2a available in October 2025 VICTORIA, British Columbia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with

    8/12/25 4:25:54 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    Eupraxia Pharmaceuticals Reports First Quarter 2025 Financial Results

    Data from Phase 1b/2a RESOLVE suggests EP-104GI has significant potential to improve the standard of care for patients with Eosinophilic Esophagitis (EoE) Cash runway to fund operations out to third quarter of 2026 Company to host webinar to discuss updated data from the RESOLVE trial on May 9th VICTORIA, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the first quar

    5/6/25 6:00:00 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

    VICTORIA, BC, March 20, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the fourth quarter of 2024. All dollar values are in U.S. dollars unless stated otherwise. "During the fourth quarter of 2024, and again in the current quarter of 2025, we delivered compelling data from our Phase 1b/2a RESOLVE trial for EP-

    3/20/25 5:30:48 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    $EPRX
    Leadership Updates

    Live Leadership Updates

    View All

    Eupraxia Pharmaceuticals Announces CFO Succession

    -  Bruce Cousins is retiring, and former CFO Alex Rothwell will assume the role VICTORIA, BC, Feb. 18, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company, today announced that it has appointed Alex Rothwell as the Company's new Chief Financial Officer, effective immediately. Bruce Cousins, the Company's outgoing CFO, is retiring and will remain in a consultant role in the near-term to ensure an orderly transition of the CFO responsibilities. "Having previously served as Eupraxia's CFO

    2/18/25 7:00:00 AM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million

    VICTORIA, BC, Oct. 31, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX:EPRX) (NASDAQ:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, is pleased to announce that it has completed a non-brokered private placement of 8,905,638 Series 1 Preferred shares of the Company (the "Preferred Shares"), at a price of C$5.00 per Preferred Share for aggregate gross proceeds of C$44,528,190, by way of a non-brokered private placement (the "Private Placement").

    10/31/24 7:36:00 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    $EPRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Eupraxia Pharmaceuticals Inc.

    SC 13G - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Subject)

    11/14/24 4:17:44 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care

    SEC Form SC 13D filed by Eupraxia Pharmaceuticals Inc.

    SC 13D - EUPRAXIA PHARMACEUTICALS INC. (0001581178) (Subject)

    11/7/24 4:10:15 PM ET
    $EPRX
    Pharmaceuticals and Biotechnology
    Health Care